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Specificity for deubiquitination of monoubiquitinated
FANCD2 is driven by the N-terminus of USP1
Connor Arkinson1 , Viduth K Chaugule1, Rachel Toth2, Helen Walden1
The Fanconi anemia pathway for DNA interstrand crosslink repair
and the translesion synthesis pathway for DNA damage tolerance
both require cycles of monoubiquitination and deubiquitination.
The ubiquitin-specific protease-1 (USP1), in complex with USP1-
associated factor 1, regulates multiple DNA repair pathways by
deubiquitinating monoubiquitinated Fanconi anemia group D2
protein (FANCD2), Fanconi anemia group I protein (FANCI), and
proliferating cell nuclear antigen (PCNA). Loss of USP1 activity
gives rise to chromosomal instability. Whereas many USPs
hydrolyse ubiquitin–ubiquitin linkages, USP1 targets ubiquitin–
substrate conjugates at specific sites. The molecular basis of USP1’s
specificity for multiple substrates is poorly understood. Here, we
reconstitute deubiquitinationof purifiedmonoubiquitinated FANCD2,
FANCI, and PCNA and show thatmolecular determinants for substrate
deubiquitination by USP1 reside within the highly conserved and
extended N-terminus. We found that the N-terminus of USP1 har-
bours a FANCD2-specific binding sequence required for deubiquiti-
nation of K561 on FANCD2. In contrast, the N-terminus is not required
for direct PCNA or FANCI deubiquitination. Furthermore, we show that
the N-terminus of USP1 is sufficient to engineer specificity in a more
promiscuous USP.
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Introduction
Ubiquitination is a reversible post-translational modification that
regulates almost every cellular process in eukaryotes. Cycles of
ubiquitination and deubiquitination orchestrate the assembly and
disassembly of many DNA repair complexes in DNA damage re-
sponse pathways. These include the Fanconi anemia (FA) pathway,
required to repair DNA interstrand crosslinks (ICLs), and the
translesion synthesis pathway (TLS), required for DNA damage
tolerance (1). FA is a chromosomal instability disorder that results
from a dysfunctional ICL repair pathway (2). Central to FA ICL repair
is monoubiquitination of two homologous proteins, Fanconi ane-
mia group D2 protein (FANCD2) and Fanconi anemia group I protein
(FANCI), at two specific lysines, K561 and K523, in humans, re-
spectively. Monoubiquitination of FANCD2 and FANCI is catalysed by
the E3 ubiquitin ligase FANCL and the E2 conjugating enzyme Ube2T
(3). Monoubiquitinated FANCD2 (FANCD2-Ub) signals multiple DNA
repair proteins to conduct ICL repair (2). A similar specific modi-
fication is central to TLS repair, where K164 of proliferating cell
nuclear antigen (PCNA) is monoubiquitinated (PCNA-Ub) by the
RAD18 E3 ligase and Rad6 E2 (4), which, in turn, recruits TLS
polymerases for DNA repair (5). As well as ubiquitination, both ICL
and TLS repair require deubiquitination (removal of ubiquitin).
Interestingly, although the modifications in each pathway are as-
sembled by distinct enzymes, they are removed by the same
deubiquitinase (DUB), the USP1–USP1-associated factor 1 (UAF1)
complex (6, 7, 8). Loss of USP1 function results in an accumulation of
FANCD2, FANCI, and PCNA; genomic instability; and a failure to
complete the pathways (7, 9, 10, 11, 12). In addition to these three
substrates, USP1 deubiquitinates a number of other substrates,
including the inhibitor of DNA-binding proteins 1–4 (ID1-4), which
regulate cell differentiation (13), and TBK1, which is involved in viral
infection (14).
USP1 belongs to the largest family of DUBs, the ubiquitin-specific
proteases (USPs), which contain ~50 members. Many USPs show
little substrate discrimination between ubiquitin–ubiquitin chains
in vitro (15), and can hydrolyse polyubiquitin chains from substrates
(16). A few USPs exhibit preference for specific ubiquitin–ubiquitin
linkages, such as USP30 for K6-linked Ub chains (17). In contrast,
USP1 targetsmonoubiquitinated substrates and regulates a distinct
set of modified proteins. Although molecular mechanisms of
ubiquitin removal from ubiquitin are well understood (16), it is less
clear how ubiquitin–substrate linkages are specifically targeted.
The core catalytic USP domain is ~350 amino acids. However, most
USPs also contain multiple insertions within the catalytic domain
and additional N/C-terminal extensions (18). USP1 has multiple
insertions and an extended N-terminus on its USP domain, and
their functions are currently unknown.
USP1 has little DUB activity on its own, but is regulated by and
forms a stoichiometric complex with UAF1. UAF1 also binds and
activates two other DUBs, USP12 and USP46 (19), and studies that
reveal how UAF1 binds and activates USP12 and USP46 suggest that
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UAF1 will bind to USP1 in an analogous manner (20, 21). UAF1 acts to
stabilise its USP partners and increase catalytic activity (22). UAF1
knockout in mice is embryonic lethal, whereas USP1 knockouts result
in a FA-like phenotype, reflecting the additional functions of UAF1
(9,23). In addition to its activation role, UAF1 has a C-terminal SUMO-
like domain (SLD) responsible for recruiting USP1 indirectly to FANCD2
and PCNA via a weak interaction with SUMO-like interactingmotifs in
FANCI and ATAD5, respectively (24). Despite the common activator
function of UAF1, loss of either USP12 or USP46 does not result in
accumulation of USP1 substrates (19), suggesting that USP1 could
target its substrates independent of UAF1. However, it remains un-
clear how USP1 specifically targets its substrate pool.
Investigating how USPs deubiquitinate their substrates on a mo-
lecular level is very challenging because of the difficulty in making
physiological and correctly ubiquitinated substrates. To date, most of
our understanding of DUB specificity has used ubiquitin–ubiquitin
linkages as substrates, likely because of the advances in purifying
large quantities of ubiquitin chains. However, there are a few ex-
amples of studies that have used monoubiquitinated substrates with
a native isopeptide, and these include PCNA-Ub (25) and histones
(26). Particularly in the case of histone H2A and H2B, the generation of
monoubiquitinated substrates has facilitated the elucidation of the
mechanisms of substrate targeting by histone-specific DUBs (26, 27).
The ability to make physiological substrates allows for a modular
approach to understanding the requirements for specificity and how
DUBs such as USP1 work at the molecular level.
Here, we report the reconstitution of substrate deubiquitination by
USP1–UAF1 that allows for a modular approach to understanding the
molecular requirements for deubiquitination of physiological sub-
strates. We define the molecular determinants for substrate deubi-
quitination via a few residues in a highly conserved and extended
N-terminus of USP1. Our analysis indicates that the N-terminus of
USP1 harbours a FANCD2-specific binding sequence important for
deubiquitinating only one specific lysine on FANCD2: K561—the lo-
cation of a specific DNA repair signal. Remarkably, we find that the
N-terminus of USP1 is important for FANCD2-K561Ub deubiquitination
but apparently not for PCNA-K164Ub or FANCI-K523Ub. Finally, we find
that the N-terminus of USP1 is sufficient to engineer specificity in
amore promiscuous DUB. Our analysis shows that USP1 discriminates
between substrates and has direct elements for targeting FANCD2,
regardless of whether it is ubiquitinated, providing further insights
into how USPs select their substrates.
Results
USP1 catalytic domain is sufficient for activity and binding to UAF1
To gain insight into USP1 specificity, we analysed the amino acid
sequence and separated the protein into regions termed USP
domain, Insert 1, Insert 2, and N-terminus (Fig 1A). Several elements
important for cellular regulation have been previously identified,
such as a calpain cleavage site within the N-terminus (28), a degron
motif for anaphase-promoting complex/cyclosomeCdh1 targeting
within insertion 1 (29), and an auto-cleavage region (G670/G671)
within insertion 2 (7). However, whether these regions are important
for in vitro DUB activity is unknown. We designed multiple USP1
fragments for expression in Sf21 insect cells, keeping the catalytic
domain intact, but systematically removing the insertions and
N-terminus (Fig 1B). Each construct of USP1 is expressed and pu-
rified to homogeneity (Fig 1C). To assess catalytic activity and
competency, we used ubiquitin-propargylamine (Ub-prg), a “sui-
cide” probe which crosslinks to the active site cysteine residue of
DUBs (30). Recombinant USP1FL, in addition to all of the other
fragments, fully reacts with Ub-prg (Fig 1C), thus indicating the
catalytic domain is competent and able to bind ubiquitin. USP1FL
has multiple breakdown products, but when insertions 1 and 2 are
deleted, the yield and purity are much higher, indicating an in-
crease in protein stability. Indeed, thermal denaturation assays
reveal that USP1ΔNΔ1Δ2 is more thermostable (Tm = 44 ± 0.24°C),
whereas USP1FL melts at lower temperatures (Tm = 37 ± 0.81°C) (Fig
S1). Importantly, USP1 requires to be in complex with UAF1 for robust
proteolytic activity (22). We find that UAF1 can bind the minimal
USP1 catalytic domain (USP1ΔNΔ1Δ2) by size exclusion chromatog-
raphy (SEC) (Fig 1D) and stimulate DUB activity on a fluorescent
ubiquitinated-dipeptide substrate, Ub-KGTAMRA (Fig 1E). The cleav-
age rates show that the activity of a USP1ΔNΔ1Δ2–UAF1 complex is
almost identical to that of USP1FL–UAF1. Because aminimal pseudo-
substrate was used, we further assayed the activity against K63- and
K48-linked di-ubiquitin chains (Fig 1F) and did not detect any
differences in activity between USP1FL and USP1ΔNΔ1Δ2. Together,
these data show that the catalytic domain of USP1, with stoi-
chiometric amounts of UAF1, is sufficient for DUB activity and that
the additional regions of USP1 are not important for in vitro DUB
catalysis or UAF1 stimulated activity.
USP1–UAF1 directly deubiquitinates monomeric FANCD2-Ub and
FANCI-Ub
TheUSP1–UAF1 complex candeubiquitinate severalmonoubiquitinated
substrates, including human FANCD2-K561Ub (hsFANCD2-Ub) (6), hu-
man FANCI-K523Ub (hsFANCI-Ub) (31), and human PCNA-K164Ub
(PCNA-Ub) (25). To understand the requirements for deubiquitina-
tion, we optimised a robust method for producing full-length isolated
hsFANCD2-Ub and hsFANCI-Ub substrates. The homogeneous prepa-
ration of isolated hsFANCD2-Ub and hsFANCI-Ub is very challenging, as
previous studies required a non-mammalian FANCD2–FANCI substrate
complex, in addition to needing DNA and a six-protein E3 ligase
complex (FANCC, FANCE, FANCF, FANCB, FANCL, and FAAP100), to
stimulate the modification (32). To enhance the yield and purity of
hsFANCD2-Ub and hsFANCI-Ub, we developed a method that requires
only a FANCL fragment (FANCLΔELF) and a hyperactive mutant form of
the E2, Ube2Tv4 (33), to stimulate the reaction (see the Materials and
Methods section). Using these enzymes (Fig 2A), we observed robust
monoubiquitination of the isolated human FANCD2 and FANCI sub-
strateswithin 60minwhenmonitoredwith either fluorescent ubiquitin
(Ub800) (Fig S2A) or GST-Ub (Fig 2B). To ensure site specificity of
ubiquitination, we mutated K561 and K523 to Arg in FANCD2 and FANCI,
respectively. In contrast to WT FANCD2 and FANCI, the mutants K561R
and K523R are not monoubiquitinated using these reaction condi-
tions, indicating that site specificity is maintained (Fig 2B). We further
assessed site specificity by purifying hsFANCD2-Ub and hsFANCI-Ub
to homogeneity and analysed both modified and unmodified proteins
USP1 N-terminus determines substrate specificity Arkinson et al. https://doi.org/10.26508/lsa.201800162 vol 1 | no 5 | e201800162 2 of 15
USP1 N-terminus determines substrate specificity Arkinson et al. https://doi.org/10.26508/lsa.201800162 vol 1 | no 5 | e201800162 3 of 15
by mass spectrometry to verify whether the correct lysine was
ubiquitinated. We detected ubiquitin on FANCD2-K561 and FANCI-K523
and did not detect any secondary ubiquitination events (Fig S2B). In
addition, these reaction conditions also support monoubiquitination
of the isolated Xenopus laevis (xl) FANCD2 and FANCI substrates
without the need for any reaction cofactors (Fig S2C). Purification
profiles of both hsFANCD2-Ub and hsFANCI-Ub show no apparent
changes in their solution states or hydrodynamic radius compared
with non-ubiquitinated proteins (Fig 2C). Finally, we purified hsPCNA-
Ub using a previously described method that uses a mutant E2
(UbcH5c S22R (25)) (Fig 2C). With the substrates purified (Fig 2C),
we assessed whether hsFANCD2-Ub, hsFANCI-Ub, or hsPCNA-Ub is
directly deubiquitinated by USP1–UAF1 in vitro. The recombinant
USP1FL is able to fully deubiquitinate hsFANCD2-Ub, hsFANCI-Ub,
and hsPCNA-Ub at sub-stoichiometric concentrations, in a UAF1-
dependent manner (Fig 2D). In contrast, a catalytically dead mu-
tant of USP1 (C90S) is unable to deubiquitinate any of the substrates
(Fig 2D). Taken together, these data establish that recombinant
USP1–UAF1 is able to directly deubiquitinate diverse monoubiquitinated
substrates in vitro without the need for auxiliary factors.
The N-terminus of USP1 is critical for FANCD2-Ub deubiquitination
To understand the minimum requirements for deubiquitination, we
assessed whether the catalytic domain of USP1 is sufficient for
deubiquitinating its physiological substrates. To test this, we assayed
multiple USP1 fragments. As shown, USP1FL–UAF1 readily deubiqui-
tinates hsFANCD2-Ub, hsFANCI-Ub, and hsPCNA-Ub (Fig 3A). In
addition, the minimal catalytic module (USP1ΔNΔ1Δ2–UAF1) is suffi-
cient for deubiquitinating hsFANCI-Ub (Fig 3A). Surprisingly,
USP1ΔNΔ1Δ2–UAF1 is unable to deubiquitinate hsFANCD2-Ub and there
is slower activity on hsPCNA-Ub at early time points (Fig 3A), in-
dicating the catalytic domain is not sufficient despite the catalytic
domain being active on other substrates including hsFANCI-Ub. In
light of this unexpected result, we wanted to determine which de-
leted region of USP1 is responsible for the loss in deubiquitinating
activity on hsFANCD2-Ub. We, therefore, assayed each deletion:
USP1ΔN, USP1Δ1, and USP1Δ2. Both deletions of inserts 1 and 2 cleave at
the same rate as USP1FL; however, deletion of the N-terminus results
in a large loss of activity on hsFANCD2-Ub (Fig 3B). In contrast to
hsFANCD2-Ub, none of the deletions have any apparent effect on
hsFANCI-Ub deubiquitination or hsPCNA-Ub deubiquitination (Fig
3B). Because the minimal USP1ΔNΔ1Δ2 is still an active DUB, we
wanted to determinewhether at higher concentrationshsFANCD2-Ub
could be deubiquitinated by this fragment. Full deubiquitination of
hsFANCD2-Ub can only be achieved by increasing the concentration
of USP1ΔNΔ1Δ2 to a 1:1 ratio (Fig 3C). This is in contrast to USP1Δ1Δ2,
which is able to deubiquitinate hsFANCD2-Ub at sub-stoichiometric
concentrations (Fig 3C). These data indicate that although the
N-terminus is not required for catalytic activity per se, it indeed
contributes to a more productive hsFANCD2-Ub DUB activity.
A recent report suggests that xlFANCI is required for human
USP1–UAF1 to remove ubiquitin from xlFANCD2-Ub (32). In contrast,
we found that xlFANCD2 does not require the presence of xlFANCI to
be deubiquitinated (Fig 3A). Therefore, we speculated whether our
observation was because of the use of human FANCD2 substrate. To
test this, we purified xlFANCD2-Ub to homogeneity (Fig S2C–E) and
assayed with human USP1–UAF1. In contrast to previous reports, we
found that USP1FL and USP1Δ1Δ2 are able to fully deubiquitinate
xlFANCD2-Ub (Fig 3D). Furthermore, consistent with our observa-
tions using hsFANCD2-Ub as substrate, deletion of the N-terminus
reduces USP1 activity for xlFANCD2-Ub (Fig 3D). Because deletion of
the N-terminus of USP1 does not result in an apparent defect for
Ub-KGTAMRA (Fig 1E), K63/K48 diUb (Fig 1F), hsFANCI-Ub (Fig 3B), and
hsPCNA-Ub (Fig 3B), it is likely that the USP1 N-terminus is a specific
FANCD2-Ub requirement that is extended from the catalytic do-
main. Taken together, these data suggest that the N-terminus of
USP1 harbours a substrate targeting sequence specific for FANCD2.
The N-terminus drives specific FANCD2-K561-Ub deubiquitination
The ubiquitination site of FANCD2 is at a specific residue, K561. We
speculated whether the FANCD2 targeting by the N-terminus of
USP1 also extends to the site of ubiquitination, that is, for K561-Ub.
To test this, we generated FANCD2 and modified lysines distinct
from K561 (Fig 4A). We decided to use a mutant E2 (UbcH5cS22R) that
primarily monoubiquitinates proteins (25). As the monoubiquitination
activity was weak, we used the E3 ligase RNF4 fragment (RNF4-RING
fusion, RNF4RR) to increase the activity (34). TheUbcH5cS22R/RNF4RR pair
resulted in robust and multiple monoubiquitination events on
hsFANCD2 (Fig 4B). To ensure K561 is not being monoubiquitinated by
UbcH5cS22R/RNF4RR, we used K561R hsFANCD2 as the substrate. We
performed an E3 assay to monoubiquitinate hsFANCD2 and hsFANCD2
K561R, which we term hsFANCD2 K561-Ub and hsFANCD2 KX-Ub, re-
spectively (Fig 4A), and treated the reaction products with USP1FL–UAF1
or USP1ΔN–UAF1. Interestingly, whereas USP1FL–UAF1 deubiquitinates
both substrates K561-Ub and KX-Ub at similar rates, USP1ΔN–UAF1
shows clear activity on KX-Ub but little detectable activity on K561-Ub
(Fig 4C). These data show that the USP1 N-terminus targeting sequence
also specifies the site for DUB activity on FANCD2-Ub, that is, K561-Ub.
Comparing deubiquitination activity of E. coli– and
Sf21-expressed USP1
To determine whether the N-terminus dependence of hsFANCD2-
Ub deubiquitination by USP1 was due to possible post-translational
Figure 1. The catalytic domain of USP1 is sufficient for UAF1 binding and activation.
(A) Overall schematic of USP1 domain structure and boundaries. USP1 contains an extended N-terminus and two large insertions within the USP domain. This schematic
excludes minor insertions within the catalytic domain. Included: Degron motif (295–342) for APC/CCdh1, NLS (266–287 and 298–321), catalytic triad residues (C90, H592, and
D751), and a calpain cleavage site (S13). (B) Schematic of truncation/deletion fragments of USP1 and UAF1 used in this study. (C) Recombinant USP1 constructs from Sf21
cells incubated with threefold molar excess ubiquitin-propargylamine (Ub-prg). A band shift (*) shows crosslinking of Ub-prg to USP1. (D) SEC of recombinant USP1 with
UAF1 at 15 μM. Catalytic domain of USP1 (USP1ΔNΔ1Δ2) is sufficient for forming a complex with UAF1. (E) A comparison of DUB activity of USP1 constructs using 300 nM Ub-
KGTAMRA as a minimal substrate. Equimolar UAF1 was used as USP1 alone contains little activity. (F) Hydrolysis of K63- or K48-linked di-ubiquitin (10 μM) using 50 nM
USP1FL–UAF1 or 50 nM USP1ΔNΔ1Δ2–UAF1. Data show comparable activity of USP1FL and the catalytic domain of USP1. FL, full length; NLS, nuclear localisation signals.
Source data are available online for this figure.
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modifications in eukaryotic cells, we also expressed and purified
USP1Δ1Δ2 and USP1 ΔNΔ1Δ2 from E. coli and tested their activity (Fig S3).
A comparison of Sf21- and E. coli–expressed USP1 shows only minor
differences in activity on hsFANCD2-Ub, and confirms that the activity
depends on the N-terminus of USP1 (Fig S3A). Interestingly, a small
difference in activity is apparent for hsPCNA-Ub deubiquitination
when comparingUSP1Δ1Δ2 andUSP1 ΔNΔ1Δ2, and this difference ismore
obvious in insect cell–expressed USP1 (Fig S3B), perhaps indicating
some form of regulation within the N-terminus for targeting hsPCNA.
However, as deubiquitination of hsFANCD2-Ub still depends on the
N-terminus regardless of how USP1 is expressed, we used the E. coli
USP1 to assess point mutations within the N-terminus.
The N-terminus of USP1 contains critical residues for FANCD2-Ub
deubiquitination
To identify residues within the N-terminus of USP1 required for
hsFANCD2-Ub specificity, we looked at regions that are well conserved
Figure 2. Recombinant human FANCD2-Ub and FANCI-Ub are deubiquitinated by USP1–UAF1 in vitro.
(A) Purification of human FANCD2 and FANCI, a hyperactive mutant Ube2Tv4, FANCLΔELF, ubiquitin E1, and GST-ubiquitin. (B) Ubiquitination reactions using reaction
components in (A). FANCD2 with K561R and FANCI with K523R mutations were used as a control for lysine specificity. (C) Purity of monoubiquitinated human hsFANCD2 and
hsFANCI, and SEC comparing modified and unmodified hsFANCD2 and hsFANCI. (D) Deubiquitination (40 min) of 1 μM hsFANCD2-Ub, hsFANCI-Ub, and hsPCNA-Ub by 100 nM
USP1 with and without UAF1.
Source data are available online for this figure.
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within the N-terminus of USP1 (Fig 5A). The N-terminus of USP1 is
almost completely conserved from humans to zebrafish between
residues 19 and 40 (Fig 5A). Similar to deleting residues 1–54 of USP1,
deletion of residues 21–29 also results in a specific loss in activity
for hsFANCD2-Ub but not hsPCNA-Ub (Fig 5B). We next determined
whether any of the side chains are important, so we mutated each
residue to alanine and assayed for DUB activity using Ub-prg,
hsPCNA-Ub, hsFANCI-Ub, and hsFANCD2-Ub (Fig S4). All point mu-
tants are active with Ub-prg (Fig S4A), and deubiquitinate hsPCNA-
Ub and hsFANCI-Ub (Fig S4B). In contrast, there is a loss in activity
for several point mutants, such as N21A, R22A, L23A, S24A, and K26A,
on hsFANCD2-Ub deubiquitination (Fig S4B). To quantify the relative
differences between USP1 mutants, we purified hsFANCD2-Ub with
a fluorescently labelled Ub800 that allows us to detect only the
ubiquitinated FANCD2 (hsFANCD2-Ub800) (Fig S5). Using this ap-
proach, we monitored the deubiquitination of hsFANCD2-Ub800 by
each mutant and quantified the remaining FANCD2-Ub as a per-
centage of the input (Fig 5C). We found that whereas USP1Δ1Δ2–UAF1
cleaves ~80% of the hsFANCD2-Ub800, USP1ΔNΔ1Δ2–UAF1 shows no
apparent cleavage (Fig 5C). Interestingly, R22A and L23A are able to
only deubiquitinate ~10% of the hsFANCD2-Ub800 (Fig 5C). We did
not further characterise L23A as it co-purifies with a large con-
taminant chaperone, which may suggest some misfolding (Fig S4).
We next assessed whether the charge at R22 is critical for deubi-
quitination as it is conserved as a lysine in zebrafish (Fig 5A). We
generated R22K, R22A, and R22E variants (Fig S4C), and as expected,
these had no apparent effect on hsPCNA-Ub or hsFANCI-Ub deu-
biquitination (Figs 5D and S4D). In contrast, we observed that R22A
has an intermediary affect and R22E is comparatively more com-
promised on hsFANCD2-Ub deubiquitination (Fig 5D). R22K retains
WT activity on hsFANCD2-Ub (Fig 5D), suggesting a positive charge is
required. Finally, we found that in the full-length USP1–UAF1
context, a single point mutation in its N-terminus (R22E) is sufficient
for specifically disrupting hsFANCD2-Ub deubiquitination but not
hsFANCI-Ub or hsPCNA-Ub (Fig S6A–C). Taken together, these data
indicate that R22 plays an important role in deubiquitination of
Figure 3. The N-terminus of USP1 is required for robust FANCD2-Ub deubiquitination but not for hFANCI-Ub or PCNA-Ub.
(A) Deubiquitination reactions of 1 μM recombinant hsFANCD2-Ub, hsFANCI-Ub, and 3 μM hsPCNA-Ub using 100 nM of either USP1FL–UAF1 or USP1ΔNΔ1Δ2–UAF1. (B)
Deubiquitination assays of hsFANCD2-Ub, hsFANCI-Ub, and hsPCNA-Ub using indicated USP1 truncations. (C) Full deubiquitination of 1 μM hsFANCD2 in 30min requires 10×
USP1ΔNΔ1Δ2 when compared to USP1Δ1Δ2. (D) Deubiquitination of frog (X. laevis) FANCD2 by USP1Δ1Δ2 and USP1ΔNΔ1Δ2. Proteins are separated by SDS–PAGE and stained with
Coomassie blue.
Source data are available online for this figure.
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hsFANCD2-Ub. However, it is clear that multiple conserved residues
(N21, R22, L23, S24, and K26) that are within a short N-terminal region
may play a role in driving USP1-mediated FANCD2-Ub deubiquitination.
Mutation or deletion of the USP1 N-terminus specifically and
negatively impacts FANCD2-Ub deubiquitination. We hypothesised
that this region in the N-terminus of USP1 encodes a FANCD2-
binding site. To test this, we purified UAF1 with an N-terminal Strep
tag and formed stable complexes with USP1Δ1Δ2, R22A, R22K, or
USP1ΔNΔ1Δ2. We assayed interaction with hsFANCD2 and found that a
USP1Δ1Δ2–UAF1 complex can capture the non-ubiquitinated sub-
strate (Fig S7A). In contrast, when using USP1ΔNΔ1Δ2–UAF1 as bait,
hsFANCD2 is not enriched above the levels seen in the beads
control (Fig S7A). These data indicate the USP1 binding to hsFANCD2,
which is almost completely dependent on the N-terminus of USP1.
In addition, USP1Δ1Δ2-R22A only partially interacts with hsFANCD2,
and USP1Δ1Δ2-R22K does not weaken the substrate interaction—both
results are consistent with the hsFANCD2-Ub deubiquitination assays
(Figs S7A and 5A). As USP1’s interaction with FANCD2 is dependent on
the N-terminus, we wanted to determine whether this is specific for
hsFANCD2, so we similarly assayed interactions of hsFANCI and
hsPCNA. Interestingly, we can detect a weak interaction with both
hsFANCI and hsFANCI-Ub that is unaffected by deletion of the
N-terminus (Fig S7B). We could not detect an interaction between
USP1 and hsPCNA, but we observed an interaction with hsPCNA-Ub
(Fig S7C), which is, however, not dependent on the N-terminus of
USP1. Together, these data indicate that the N-terminus of USP1
directly interacts with FANCD2.
A chimera fusion of USP1 N-terminus to the USP2 catalytic domain
provides FANCD2 specificity
Deletion of the N-terminus of USP1 does not appear to affect the
catalytic activity of the USP1 catalytic module (USP1ΔNΔ1Δ2), except in
case of FANCD2-Ub deubiquitination. We, therefore, speculated
whether the N-terminus can influence the efficiency of a distinct
DUB. To test this, we chose the catalytic domain of USP2, generally
considered a versatile/promiscuous DUB because of its lack of
substrate specificity (35). We created and purified a USP2 chimera
(USP11–60-USP2) where residues 1–60 of USP1 are present in the
N-terminal to the USP2 catalytic domain. From the in vitro assays,
we found that whereas 100 nM of USP2 is able to completely
deubiquitinate 1 μM of hsFANCD2-Ub by 40 min (Fig 6A), the
Figure 4. The N-terminus of USP1 drives specifc K561 deubiquitination of FANCD2.
(A) Schematic of hsFANCD2 monoubiquitination reactions to make monoubiquitinated hsFANCD2-K561-Ub and hsFANCD2-KX-Ub (where X denotes random lysines). (B)
Monoubiquitination of hsFANCD2 (WT) by Ube2Tv4 and FANCLΔELF is predominantly a single monoubiquitination event at K561. Monoubiquitination of hsFANCD2 K561R by
UbcH5cS22R and RNF4RR (RNF4-RING fusion) results in multi-monoubiquitination of other FANCD2 lysines. Ubiquitinated products are formed in a time-dependent manner
as shown by Coomassie staining and fluorescently labelled ubiquitin, which only shows ubiquitinated products. (C)Monoubiquitinated FANCD2-K561-Ub or FANCD2-KX-Ub
reactions were arrested by treating with apyrase and subjected to deubiquitination by either USP1FL–UAF1 or USP1ΔN–UAF1. Fluorescent ubiquitin is used to monitor
ubiquitinated species and quantify DUB activity. Data show intensities as percent of ubiquitinated input (n = 3) ± SD.
Source data are available online for this figure.
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chimeric USP11–60-USP2 achieves this within 10 min (Fig 6A),
showing a clear gain of activity. Because the N-terminus increases
USP2 activity against FANCD2-Ub, we tested whether the N-terminus
augments its activity towards other ubiquitinated substrates. In
contrast to hsFANCD2-Ub, there are no obvious differences in the
activity of USP2 and the USP2 chimera using hsFANCI-Ub as the
substrate (Fig 6B). In addition, only minor differences in the deu-
biquitination activity of hsPCNA-Ub are observed at early time
points (Fig 6C). These data show that the addition of USP1 N-terminus
in cis confers a gain of activity for USP2 on hsFANCD2-Ub.
FANCD2–FANCI–DNA complex deubiquitination depends on the
N-terminus of USP1
The FANCD2 and FANCI substrates can form a heterodimer on DNA,
and this ensemble has been shown to be important for in vitro
monoubiquitination (32, 36, 37). However, it is not yet known how the
monoubiquitinated FANCD2 and FANCI proteins assemble or in-
teract once modified. It is, therefore, unclear whether hsFANCD2-Ub
is deubiquitinated as part of a complex or on its own. A recent
report has showed that the di-monoubiquitinated frog ID2 complex
(both FANCD2 and FANCI monoubiquitinated), generated in the
presence of plasmid DNA, remains resistant to deubiquitination by
a GST-tagged USP1–UAF1 complex and only the removal of DNA
permits efficient DUB activity (32). Because under physiological
conditions the monoubiquitinated ID2 complex is normally local-
ized on DNA, we therefore wanted to test whether deubiquitination
of the hsID2–DNA complex is also dependent on the N-terminus of
USP1. To test this, we first monoubiquitinated the hsID2 hetero-
dimer in the presence of double stranded DNA (dsDNA) (36) and
arrested the ubiquitination reactions with apyrase. We sub-
sequently treated half of the substrate sample with benzonase
nuclease to eliminate the DNA before subjecting both the nuclease-
treated and untreated substrate samples to USP1–UAF1 activity.
Whereas USP1FL is able to deubiquitinate some of the hsFANCD2-Ub
in the presence of both DNA and hsFANCI, a portion of hsFANCD2-Ub
and hsFANCI-Ub remains resistant to deubiquitination (Fig 7A),
consistent with the recent findings using frog substrates (32). In-
terestingly, when DNA is removed, all of the hsFANCD2-Ub and
hsFANCI-Ub is deubiquitinated by USP1FL–UAF1; in contrast,
USP1ΔN–UAF1 and USP1R22E–UAF1 do not deubiquitinate hsFANCD2-
Ub (Fig 7A). To allow a clear assessment of whether DNA, FANCI-Ub,
or both factors inhibit deubiquitination, we monoubiquitinated
FANCD2–FANCIK523R–DNA complexes. Using this set-up, we observed
that USP1FL–UAF1 is able to deubiquitinate hsFANCD2-Ub-FANCI with
and without benzonase treatment (Fig 7B). These data suggest that
Figure 5. Several highly conserved residues within USP1 N-terminus determine FANCD2-Ub deubiquitination.
(A) Sequence alignment of USP1 N-terminus from several species (hs, Homo sapiens; mm,Mus mucus; bt, Bos taurus; gg, Gallus gallus; xl: X. laevis; dr, Danio rerio). Deleted
USP1 residues in (B) and residues important for acitivity (bold) in (C) are indicated. (B) Deubiquitination assay of hsFANCD2-Ub and hsPCNA-Ub using E. coli–purified
USP1Δ1Δ2, USP1ΔNΔ1Δ2, and USP1Δ21-29Δ1Δ2 in complex with UAF1. (C) Deubiquitination assays of hsFANCD2-Ub800 by recombinant USP1Δ1Δ2 with Ala point mutants from E. coli.
The loss in fluroescence intensity was quantified and normalised to the amount of input hsFANCD2-Ub800. Data display mean residual FANCD2-Ub800 (%) (n = 3) ± SD
normalised to input. (D) Deubiquitination assays of hsFANCD2-Ub for 40min using USP1Δ1Δ2 with R22 point mutations indicate that a positive charge at position 22 is critical
for hsFANCD2-Ub deubiquitination but not for hsFANCI-Ub or hsPCNA-Ub.
Source data are available online for this figure.
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DNA does not inhibit FANCD2-Ub deubiquitination except in the
context of the di-monoubiquitinated ID2–DNA complex. Interestingly,
and despite the presence of FANCI, which may also recruit the DUB
complex (24), USP1ΔN–UAF1 and USP1R22E–UAF1 are not able to fully
deubiquitinate hsFANCD2-Ub, suggesting that any indirect recruit-
ment of USP1–UAF1 by FANCI does not completely compensate for the
loss of the USP1 N-terminus. Thus, the N-terminus of USP1 contains
a FANCD2 determinant sequence that functions at the core of FANCD2
Figure 6. The N-terminus provides a gain of FANCD2-
Ub activity when fused to USP2.
(A) Deubiquitination of 1 μM FANCD2-Ub by either 100
nM of E. coli–expressed USP1Δ1Δ2–UAF1,
USP1ΔNΔ1Δ2–UAF1, rat USP2 catalytic domain (USP2cat),
or USP1(1–60)-USP2cat chimera, where residues 1–60 of
USP1 are fused to the N-terminus of USP2’s catalytic
domain. Coomassie-stained FANCD2-Ub was scanned
and intensity of the FANCD2-Ub band measured over
time. Data show mean residual FANCD2-Ub signal (% of
input) plotted against time (n = 3) ± SD. (B) 1 μM FANCI-
Ub and (C) 3 μM PCNA-Ub deubiquitination as above.
Data show mean residual FANCI-Ub or PCNA-Ub signal
(% of input) plotted against time (n = 3) ± SD.
Source data are available online for this figure.
Figure 7. The N-terminus of USP1 is required for FANCD2-Ub deubiquitination when in complex with FANCI and DNA.
(A) Deubiquitination of di-monoubiquitinated FANCD2–FANCI complex with and without DNA by USP1FL–UAF1, USP1ΔN–UAF1, and USP1R22E–UAF1. A FANCD2–FANCI–ds DNA
complex is monoubiquitinated by Ube2Tv4, FANCLΔELF, E1, and ubiquitin for 30 min and reactions arrested using apyrase. Ubiquitination reactions are treated with
benzonase nuclease for 4 h on ice before being subject to USP1 for 30min at room temperature. FANCD2 and FANCI are detected by Coomassie staining or Western blotting
on the same nitrocellulose membrane and visualised using anti-FANCD2 or anti-V5 (FANCI). (B) Assay performed as in (A) except that FANCI with a K523R mutation is used.
(C) Model of FANCD2-Ub deubiquitination by USP1–UAF1. USP1 targets FANCD2 via a direct interaction using its N-terminus. In addition to the N-terminus of USP1,
FANCD2–Ub–FANCI complexes might be indirectly targeted by an interaction between UAF1 SLD and FANCI SUMO-like interacting motif (SLIM).
Source data are available online for this figure.
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deubiquitination by specifically binding and increasing deubiquiti-
nation efficiency for FANCD2-Ub even in the presence of both dsDNA
and FANCI (Fig 7C).
Discussion
A cycle of monoubiquitination and deubiquitination of FANCD2 is
critical for completion of FA ICL repair (8). Removal of the ubiquitin
signal from FANCD2 is conducted by the USP1–UAF1 DUB, and
disruption of USP1 catalytic activity results in an accumulation of
FANCD2-Ub and FA-like phenotypes (6, 9, 11, 23). Despite multiple
DUBs existing at DNA replication and repair events, USP1 appears to
be the only DUB whose loss results in an accumulation of FANCD2-
Ub (6). The molecular determinants and mechanisms of how DUBs,
such as USP1, target and regulate distinct pools of substrates have
remained elusive, because of a lack of molecular insights. Here, we
report a unique feature and a potential short linear motif at the
N-terminus of USP1, which shows that USP1 specifically and directly
targets K561 of FANCD2, providing a molecular foundation for how
USP1 targets one of its substrates with high specificity.
USP1 activity is subject to layers of regulation during cell-cycle
progression. For example, USP1 is turned over throughout the cell
cycle, is activated and stabilised by binding partners such as UAF1,
and, in addition, undergoes autocleavage to allow targeting by both
the N-end rule and C-end rule pathways (7, 11, 22, 38). Interestingly,
UAF1 is an abundant protein with multiple functions, including
activating USP12 and USP46 (19). It has been suggested that UAF1
may indirectly target USP1 to specific substrates such as FANCD2 or
PCNA via a C-terminal SLD that binds to SUMO-like interacting
motifs on protein partners of FANCD2 and PCNA (24) (Fig 7C).
However, disruption of either USP12 or USP46 does not affect
FANCD2-Ub levels, showing that FANCD2 is not an overlapping
substrate (19). Because the SLD of UAF1 would target multiple DUBs
to the same substrates, further layers of regulation may exist to
ensure the correct DUB is targeted to FANCD2-Ub or PCNA-Ub. By
reconstituting FANCD2-Ub, FANCI-Ub, and PCNA-Ub deubiquitina-
tion by USP1–UAF1, we identified the minimal components required
for deubiquitination and discovered a unique sequence within the
N-terminus of USP1 critical for removing ubiquitin from FANCD2 (Fig
7C). We noticed a relatively small, but reproducible difference in
activity on PCNA-Ub, which is apparent when deleting the N-terminus.
Dependence on the N-terminus for PCNA-Ub deubiquitination may
become more apparent when PCNA-Ub is within physiological con-
texts, such as being DNA bound and interacting with proteins such
as polη (5). Further studies may reveal additional layers of speci-
ficity for substrates such as PCNA-Ub, which could also be medi-
ated by the N-terminus of USP1–UAF1. Moreover, it remains unclear
whether the insertions of USP1 play a more direct role in substrate
specificity and deubiquitination.
The N-terminus of USP1 binds specifically to FANCD2, and not
FANCI or PCNA. Thus, USP1 appears to display a higher level of
substrate targeting for FANCD2. It is interesting that the N-terminus
of USP1 is not required for FANCI-Ub deubiquitination in vitro
because FANCI shares a similar ubiquitination site with FANCD2
both structurally (39) and on a sequence level, allowing us to
speculate that perhaps FANCD2 is the major substrate of USP1.
Although we showed that FANCD2-Ub with FANCI and DNA does
not obviously affect USP1–UAF1 deubiquitination in vitro, FANCI
has been shown to regulate FANCD2 deubiquitination in cells via
phosphomimetic mutations (40) and SUMO-like interacting motif
mutations (24). Therefore, under certain conditions, FANCI may also
play a role in the direct regulation of FANCD2-Ub deubiquitination.
For example, we and others have shown that di-monoubiquitinated
DNA-bound ID2 complexes remain resistant to deubiquitination
(32), suggesting that FANCD2-Ub and FANCI-Ub in the presence of
DNA reciprocally regulate their deubiquitination by USP1–UAF1.
How di-monoubiquitination of ID2–DNA regulates the ability of
USP1–UAF1 to remove ubiquitin from FANCD2 will be an interesting
mechanism to investigate. For example, does the ID2–DNA complex
affect the USP1 N-terminus binding or directly occlude the ubiquitin
tail from proteolytic cleavage?
The N-terminus of USP1 is an extension of the USP domain and
is ~75 amino acids in length. It is unclear how flexible, structured, or
compact the N-terminus will be in a relative position to the USP
domain and catalytic site. Interestingly, the N-terminus is modular,
as it can be added to other DUB catalytic domains such as USP2 and
enhance FANCD2-Ub–specific deubiquitination. Therefore, it is
difficult to predict whether the N-terminus of USP1 directly con-
tributes to catalysis when FANCD2 is bound, or simply acts to recruit
FANCD2-Ub and stabilise the isopeptide bond within the active site.
Because USP1ΔN–UAF1 loses activity for ubiquitinated K561, but not
for other lysines of FANCD2, this allows us to speculate that the
N-terminus binds and precisely positions FANCD2 to increase ac-
tivity for a specific lysine position. Another possibility is that
FANCD2-K561-Ub is not in a fully accessible conformation for
deubiquitination and that the N-terminus modulates this confor-
mation to allow the formation of a more productive complex. This is
reminiscent of a recently identified monoubiquitination site of
SETDB1, which protects the ubiquitin from deubiquitination via
multiple SETDB1–ubiquitin interactions (41). Perhaps FANCD2 also
partially protects and occludes ubiquitin at K561, and the N-terminus
of USP1 is required to relieve this effect. It will be interesting to de-
termine how the N-terminus binds to FANCD2, how it modulates USP1
function towards FANCD2, andwhether other PTMs or processes within
the N-terminus can modulate its function.
It is not understood how the majority of USPs target their
substrates specifically. Some USPs target the signal itself; for ex-
ample, USP18 targets ISG15 (42) and USP30 targets K6-linked
ubiquitin chains (17, 43). However, here we have an example:
USP1, which we have shown targets a specific monoubiquitinated
substrate and, therefore, recognises both ubiquitin and the sub-
strate itself. Another specific monoubiquitinated substrate is his-
tone 2B, which is monoubiquitinated on K120 and targeted by the
Spt-Ada-Gcn5 acetyltransferase (SAGA) DUB module, which con-
tains USP22 (UBP8 homologue). Whereas UBP8 has contributions
for targeting nucleosomes, other members of the complex such as
sgf11makemore significant contributions via the acidic patch on H2A/
H2B, and therefore likely govern most of the substrate specificity (27).
Whereas SAGA DUB achieves specificity via a protein complex, other
DUBs such as USP7 contain substrate-targeting regions within the
same polypeptide. USP7 displays substrate-targeting regions via
its N-terminal tumor necrosis factor–receptor associated factor-like
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domain for p53 (44). However, in contrast to the effect we see with
the disruption of USP1’s N-terminus on FANCD2-Ub deubiquitination,
disruption of the N-terminus of USP7 has only a minor effect on p53
deubiquitination in vitro (45). We show that USP1 specifically targets
one ubiquitinated lysine made by a specific E3 ligase, FANCL. Another
DUB, USP48, was recently published to also specifically oppose the
monoubiquitination made by another lysine-specific E3 ligase, BRCA1
(26). This suggests that some DUBs and E3 activities may have co-
evolved to oppose each other on specific cellular signals andmaintain
an appropriate equilibrium of non-ubiquitinated and ubiquitinated
substrates.
Arguably, the most important known function of USP1 is to
regulate FANCD2, as the monoubiquitinated form is important for
both ICL repair and origin of replication firing in latent conditions
(46). In addition, non-ubiquitinated FANCD2 is important in DNA
surveillance mechanisms (47), meaning the presence of both
FANCD2-Ub and FANCD2 is important for DNA integrity and cell
proliferation. Moreover, USP1 depletion increases oncogene-
induced senescence and plays a pivotal role in protecting geno-
mic instability by preventing FANCD2-Ub aberrant aggregation (12).
USP1–UAF1, therefore, works to recycle and maintain appropriate
levels of both monoubiquitinated and non-ubiquitinated FANCD2.
Inhibition of USP1–UAF1 activity by the specific small molecule
ML323 leads to an increased sensitivity to platinum-based com-
pounds in resistant cells (11). Furthermore, the USP1–UAF1 complex
has been shown to play critical roles in homologous recombination
(10). This collection of studies reveals that USP1 would be an ex-
cellent anticancer target by disrupting its ability to deubiquitinate
FANCD2-Ub, as this would lead to oncogene-induced senescence
and cellular sensitivity to crosslinking agents (8, 9). However,
USP1–UAF1 targets multiple substrates, including the inhibitor of
DNA-binding proteins and TBK1, meaning a catalytic activity in-
hibitor may affect multiple processes. It is possible that a more
specific inhibitor could block FANCD2–USP1 interaction, such as the
N-terminus, and may provide a more specific therapy.
Materials and Methods
Cloning
Complementary DNA for human full-length USP1FL with G670A/
G671A (mutated autocleavage site (7)) was ligated into a pFAST-
BAC vector with a TEV cleavable His tag by BamH-Not1 restriction
cloning. Subsequently, truncations of USP1 were made in the full-
length background by PCR mutagenesis: N-terminus (Δ1–54), In-
sertion 1 (Δ229–408), and Insertion 2 (Δ608–737). UAF1 was ligated
into a pFASTBAC vector with an N-terminal His-3C tag using BamH1-
Not1. Mutagenesis was used to add a Strep11 tag and a linker
“GGSGGS” N-terminal of the His-tag. X. laevis FANCD2 and X. laevis
FANCI genes were a kind gift from Puck Knipscheer (Hubrecht In-
stitute, Utrecht); the genes were ligated into pFASTBAC vectors using
EcoRI-XhoI and mutated to contain N-terminal His-TEV-HA and His-
TEV-V5 tags, respectively. Human FANCD2 gene was synthesised
by GeneArt Gene Synthesis (Invitrogen), expression optimised for
Spodoptera frugiperda, and subsequently cloned into a pFASTBAC
vector with a His-3C tag using BamH1-Not1.
USP1Δ1Δ2 gene expression optimised for E. coliwas synthesised by
GeneArt Gene Synthesis (Invitrogen) and subsequently ligated into
a pGEX6bp vector containing GST-3C tag by using BamH1-Not1. USP1
amino acids 1–60 (N-terminal) were amplified with BamH1 at either
end for ligation into a pGex6bp1 vector containing the rat USP2
catalytic domain (GST-3C-USP11–60-rUSP2 (271–618)). A mutant
Ube2T with E54R, P93G, P94G, 1–152 (Ube2Tv4) is described in
Chaugule et al, (33). The FANCLΔELF (109–375) gene was cloned into
a pET-SUMO (Invitrogen) vector using restriction-free cloning.
Tagless ubiquitin, His-TEV ubiquitin, and His-TEV-PCNA are pre-
viously described (22, 48). RNF4 (RNF4-RING domain fusion (34)) was
a kind gift from Ron Hay (University of Dundee). To introduce point
mutations or truncations, PCR mutagenesis was performed using
KOD Hot Start DNA polymerase by following the manufacturer’s
instructions.
Protein expression and purification
Baculovirus were generated using the EMBacY MultiBac system
(Geneva Biotech), and USP1, UAF1, FANCD2, and FANCI proteins were
expressed for ~72 h in baculovirus-infected Sf21 cells. FANCLΔELF,
PCNA, ubiquitin constructs, RNF4RING-RING, and E2s were expressed
and purified in BL21 E. coli, as previously described (34, 48). USP1Δ1Δ2
and USP2 were expressed using BL21 E. coli, grown to OD600: 0.6 and
induced with 0.1 μM IPTG for 18 h at 16°C. Fluorescently labelled
ubiquitin was made as described previously (42).
All steps of purifications were performed at 4°C and completed
within 24–36 h of lysis. Cell pellets were routinely suspended in lysis
buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 5% glycerol, 10 mM im-
idazole, 10 mM 2-mercaptoethanol with freshly added MgCl2 [2 mM],
protease inhibitor [EDTA-free] tablets, and benzonase). For FANCD2,
FANCI, and FANCLΔELF, the lysis buffer contained 400 mM NaCl. Sf21
cells were lysed by a homogeniser, followed by sonication at 40%
amplitude, 10 s on/10 s off for 12 cycles. Suspended E. coli cells were
sonicated at 80% amp, 20 s on/40 s off for 12 cycles. All lysates
were clarified at 40,000 g for 45 min and filtered (0.45 μM). Proteins
were bound to respective resins (either Ni-NTA for His tags or glu-
tathione [GSH] for GST tags) and washed extensively with lysis buffer
with 500 mM NaCl. GST-tagged proteins were eluted by incubation
with GST-precision protease or lysis buffer with 10 mM GSH. His-
Smt3–tagged proteins were eluted by on-column cleavage using
His-ULP1 protease. His-TEV– or His-3C–tagged proteins were eluted
by lysis buffer with 250 mM imidazole and lower NaCl for ion ex-
change chromatography (typically 100 mM NaCl). To remove tags,
proteins were incubated with respective proteases (His-TEV pro-
tease or GST-precision protease) overnight and tagged proteases
were removed by binding to respective resins. Tags were not re-
moved from FANCD2, FANCI, USP2, or GST-ubiquitin. Anion exchange
for USP1, UAF1, FANCD2, FANCI, GST-USP2, GST-Ub, and PCNA was
performed using a high-performance Q (1 or 5 ml) column and
the column eluted with a linear gradient (50 mM Tris, pH 8.0,
100–1,000 mM NaCl, 5% glycerol, and 10 mM 2-mercaptoethanol).
E. coli–expressed USP1 was not purified by anion exchange.
Proteins were further purified using SEC. FANCD2 and FANCI were
fractionated using an S6 Increase (10/300) column in 20mM Tris, pH
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8.0, 400 mM NaCl, 5% glycerol, and 5 mM DTT. USP1, UAF1, and E3s
were fractionated using an SD200 Increase (10/300) column in
20 mM Tris, pH 8.0, 150 mM NaCl, and 5% glycerol with 5 mM DTT. All
ubiquitin constructs and E2s were fractionated using an SD75 (10/
300) column in 20 mM Tris, pH 8.0, 150 mM NaCl, 5% glycerol, and
0.5 mM Tris 2-carboxyethyl-phosphine (TCEP). Proteins were con-
centrated to ~5 mg/ml for FANCD2/FANCI, ~4 mg/ml for FANCLΔELF,
and ~10 mg/ml for all other proteins before flash freezing in liquid
nitrogen and storage at −80°C.
Analytical gel filtration of USP1–UAF1 complexes
Recombinant USP1 and UAF1 alone or together were incubated at
15 μM for 15 min on ice before fractionation on an SD200 Increase
(10/300) column in 20mM Tris, pH 8.0, 150mMNaCl, 5% glycerol, and
5mMDTT. Samples (10 μl) weremixed with SDS–PAGE loading buffer
(10 μl) and analysed via SDS–PAGE (9%) and Instant Blue Coomassie
staining (Expedeon). All USP1 constructs were co-eluted with UAF1.
Ub-prg
BL21 E. coli carrying Ub-intein-CBD was grown to OD600: 0.6, induced
with 0.5 μM IPTG and expressed for 24 h at 16°C. Cells were har-
vested and suspended in 50 mM Na2HPO4, pH 7.2, 200 mM NaCl, and
1 mM EDTA before lysis and clarification. Lysates were bound to
chitin resin and washed extensively in 50 mM Na2HPO4, pH 7.2, and
200 mM NaCl. The resin was washed with wash buffer (20 mM
Na2HPO4, pH 6.0, 200 mM NaCl, and 0.1 mM EDTA) before incubation
overnight at 4°C with wash buffer containing 100 mM MESNa. The
eluent was collected and a second elution was performed in wash
buffer plus 100 mM MESNa. The ubiquitin-MESNa was concentrated
to ~5 ml and buffer exchanged into 50 mM Hepes, pH 8.0. Ubiquitin-
MESNA was either stored at −80°C or directly reacted with 0.25 M
propargylamine (prg) for 4 h at 20°C with mild shaking in the dark.
Ub-prg was finally purified using SD75 (16/60) in 50 mM Hepes,
pH 8.0, and 150 mM NaCl, and flash frozen for storage at −80°C.
Reacting Ub-prg with DUBs
To crosslink DUBs with Ub-prg, DUBs (2 μM) in 20 μl were incubated
in DUB buffer (50 mM Tris, pH 7.5, 120 mM NaCl, and 10 mM DTT) with
and without Ub-prg (6 μM) for 10 min at room temperature. Re-
actions were stopped by the addition of SDS–PAGE loading buffer
(Invitrogen) and visualised using 4–12% Bis-Tris SDS–PAGE (Invi-
trogen) run with NuPAGE MOPs SDS running buffer (Thermo Fisher
Scientific) and Coomassie staining. A slower migrating band in-
dicates reaction with Ub-prg.
Thermofluor assays
Thermofluor experiments were carried out using a CFX96 real-time
PCR detection system (Bio-Rad). Samples containing USP1 (40 μl) at
0.05–0.2 mg/ml in 50 mM Tris, pH 8.0, 120 mM NaCl, 10 mM DTT, and
5× SYPRO orange were dispensed in 96-well plates. The samples
were heated from 25°C to 95°C with increments of 1°C/min, and
fluorescence was measured at each interval. Data were analysed as
previously described (49), and a mean Tm°C was calculated from
three different USP1 concentrations performed in triplicate.
Fluorescent polarisation (FP) assays with ubiquitin-TAMRA assays
USP1–UAF1 samples were prepared by diluting USP1 variants (10 μM)
and UAF1 (10 μM) in DUB buffer for 10 min at room temperature. For
FP assays, USP1–UAF1 samples were diluted and incubated in DUB
buffer with 0.1 mg/ml ovalbumin at 2× concentration indicated in
reaction. Typically, reactions with Ub-KGTAMRA (UbiQ) were started
by adding and mixing 10 μl of 2× DUB (20 nM) to 10 μl 2× Ub-KGTAMRA
(600 nM) to make a final concentration of 300 nM substrate with 10
nM DUB with a volume of 20 μl. Reactions were monitored at 25°C
for 1 h by measuring FP at 2-min intervals in 384-well round-bottom
corning black plates with a PHERAstar FSX. FP values for each well
were fitted using a “one-phase decay” model in Prism (GraphPad).
pMax was monitored using Ub-KGTAMRA without DUB and pMin using
KGTAMRA.
Purifying monoubiquitinated proteins
Purification of PCNA monoubiquitinated at K164 (PCNA-Ub) was
performed as previously described (25). Monoubiquitinated FANCD2
at K561 and FANCI at K523 were purified using GST-Ub, which leaves
a “GPLGS” over hang at the N-terminus of ubiquitin following
precision protease cleavage. Typically, purified FANCD2 or FANCI
(after anion exchange) at 4 μM was monoubiquitinated by equi-
molar Ube2Tv4, FANCLΔELF, 50 nM E1, and 8 μM GST-3C-ubiquitin in
E3 buffer (50 mM Tris, pH 8.5, 150 mM NaCl, 5% glycerol, 1 mM TCEP,
2.5 mM MgCl2, and 2.5 mM ATP) for 30 min at room temperature.
xlFANCD2 ubiquitination was performed for 10 min rather than
30 min. Reactions were arrested using apyrase followed by anion
exchange chromatography (high-performance Q 1 ml). Impor-
tantly, prolonged incubation of FANCD2 in low NaCl concentrations
(below ~200 mM NaCl) will lead to large losses in protein. GST-Ub-
substrates were bound to GSH resin at 4°C before extensive washes
using 50 mM Tris, pH 8.0, 400 mM NaCl, 5% glycerol, and 2 mM DTT.
Ubiquitinated proteins were eluted from GSH resin using GST-
precision protease. Finally, ubiquitinated substrates were purified
via gel filtration using an S6 Increase (10/300) column in 20 mM
Tris, pH 8.0, 400 mM NaCl, 5% glycerol, and 5 mM DTT before
concentrating to ~5 mg/ml and flash freezing in liquid nitrogen for
storage at −80°C. Ubiquitinated FANCD2 or FANCI proteins were
visualised on Bis-Tris 4–12% gradient SDS–PAGE gels run in MOPs
SDS running buffer, the gels were “overrun” so the 20-kD reference
band in the Precision Plus prestained protein ladder (Bio-Rad)
was at the bottom of the SDS–PAGE gel. To purify FANCD2-Ub800,
FANCD2 was monoubiquitinated with ubiquitin800 instead of GST-Ub,
and subsequently purified by anion exchange and gel filtration as
above.
Mass spectrometry
Recombinant FANCD2, FANCI, FANCD2-Ub, and FANCI-Ub (10 μg)
were denatured in 7 M urea and 100 mM Tris, pH 8.0, buffer followed
by treatment with 5 mM TCEP (10 min), 5 mM idoacetamide (20 min),
and 5 mM DTT (20 min). Samples were diluted 1:10 in 100 mM Tris, pH
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8.0, and trypsin was added at 1:50 wt/wt with incubation at 37°C
overnight; finally, 1% TFA was added. The peptides were subjected
to mass spectrometric analysis performed by LC-MS-MS on a linear
ion trap-Orbitrap hybrid mass spectrometer (Orbitrap-VelosPro;
Thermo Fisher Scientific) coupled to a U3000 RSLC HPLC (Thermo
Fisher Scientific). Data files were analysed by Proteome Discoverer
2.0 (www.ThermoScientific.com), using Mascot 2.4.1 protein identi-
fication software (www.matrixscience.com) by searching against an
in-house protein database.
Deubiquitination reactions using recombinant substrates
USP1–UAF1 complexes were assembled and used to make 2× DUB
stocks at 200 nM, or as indicated in Fig 3C. Ubiquitinated substrates
were made as 2× stocks: purified hsFANCD2-Ub (2 μM), hsFANCI-Ub
(2 μM), hsPCNA-Ub (6 μM), xlFANCD2-Ub (2 μM), and diubiquitin
chains (20 μM) were incubated in DUB buffer on ice for 10 min. To
initiate hydrolysis, DUBs (200 nM) and substrates (2 or 6 μM) were
incubated in a 1:1 ratio (typically 5 μl: 5 μl) for 30 min at room
temperature or an indicated time. Reactions were terminated using
SDS–PAGE loading buffer (Invitrogen). To analyse deubiquitination,
~300 ng of FANCD2-Ub or FANCI-Ub, ~600 ng of PCNA-Ub, or 800 ng of
diubiquitin was separated on 4–12% Bis-Tris SDS–PAGE gels and
Coomassie stained. Deubiquitination was determined by the loss of
ubiquitinated proteins or the emergence of non-ubiquitinated
substrates and monoubiquitin. For USP2 DUB assays, the in-
tensity of ubiquitinated substrates was measured using a 700-nm
channel after Coomassie staining, calculated as mean % of the
input and plotted against time, with error bars showing standard
deviation from the mean.
Ubiquitination reactions
FANCD2 at K561 and FANCI at K523 were ubiquitinated at room
temperature in E3 reaction buffer using Ube2Tv4 and FANCLΔELF. For
small-scale reactions (10–100 μl), protein concentrations were
typically 2 μM substrate/E2/E3, 4 μM ubiquitin, and 50 nM E1. To
ubiquitinate FANCD2 at alternative lysines to K561 (i.e., FANCD2-KX-
Ub), FANCD2 K561R was ubiquitinated using 50 nM E1, 4 μM ubiq-
uitin800, 0.5 μM UbcH5cS22R, and 0.2 μM RNF4RR in E3 reaction buffer
at room temperature. FANCD2–FANCI–dsDNA complexes were
mixed in a ratio of 1:1:2 on ice in 50 mM Tris, pH 7.5, 100 mM NaCl, 5%
glycerol, and 1 mM DTT for at least 30 min before being ubiquiti-
nated for 30 min at room temperature using tagless Ub. The dsDNA
oligo used is an 84-nucleotide duplex made from a combination of
oligos 10 and 11 from Longerich et al (36). Reactions were stopped
by the addition of 3× SDS–PAGE loading buffer, or if used for
subsequent DUB reactions, the sample was treated with apyrase
for 5 min on ice. Ubiquitination was analysed via 4–12% Bis-Tris
SDS–PAGE and Odyssey licor CLx with an 800-nm channel for
ubiquitin800, Western blotting, and/or Coomassie staining.
DUB-step reactions
DUB-step reactions followed three steps: (1) ubiquitination (see the
Ubiquitination reactions section), (2) arrest with apyrase to stop
ubiquitination, and (3) deubiquitination. Briefly, FANCD2 (2 μM)
ubiquitinated on K561 or KX was immediately diluted 5 μl: 5 μl with
DUBs (200 nM) diluted in DUB buffer, giving a final concentration of
DUB at 100 nM and FANCD2 at 1 μM. DUB-steps were left at room
temperature for an indicated duration (usually 30 min), and 300 ng
of FANCD2-Ub800 was visualised on SDS–PAGE (4–12% Bis-Tris) with
an 800-nM channel followed by Coomassie staining. The percentage
of residual FANCD2-Ub800 was calculated as a percentage of the input
and plotted for each DUB. For non-fluorescent FANCD2–Ub–FANCI–
DNA complexes, 300 ng of FANCD2 was loaded on 4–12% Bis-Tris
SDS–PAGE for Coomassie staining and 50 ng for Western blotting.
Pull-down assays
N-terminal Strep-tagged UAF1 was complexed with E. coli–
expressed USP1Δ1Δ2 or USP1ΔNΔ1Δ2. Subsequently, 10 μg of USP1–UAF1
was bound to 10 μl MagStrep-avidin beads equilibrated in pull-
down buffer (50 mM Tris, pH 7.5, 120 mM NaCl, 5% glycerol, 1 mM DTT,
0.01% Triston X-100, and 0.01% ovalbumin) for 1 h on ice. Unbound
USP1–UAF1 complexes were washed from beads with 3× 60 μl
washes. USP1–UAF1 beads were then divided into separate tubes
(10 μl beads + 10 μl buffer) and 10 μg of recombinant substrate was
added and incubated for 1 h on ice with gentle agitation. The
supernatant was removed and the beads were washed 3× with 40 μl
buffer. Protein was eluted by suspending the beads in 20 μl pull-
down buffer and 10 μl 3× SDS–PAGE loading buffer and boiling for
2 min. Samples (10 μl) were run on 4–12% Bis-Tris SDS–PAGE gels.
Beads without USP1–UAF1 were also incubated with the substrate
to control for nonspecific binding to beads.
Western blots and antibodies
SDS–PAGE-separated proteins were transferred to nitrocellulose
membranes and blocked with 5% milk TBS-T (0.05% tween) before
incubation with 1:1,000 anti-FANCD2 (Ab2187; Abcam), 1: 5,000 anti-
V5 (66007.1-Ig; ProteinTech), or 1: 2,000 anti-PCNA (Ab29; Abcam)
overnight at 4°C. Membranes were washed 3× with TBS-T before
incubation with secondary antibodies for 1 h at room temperature
and washed with TBS-T. Results were visualised on licor using an
800- or 700-nm channel.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201800162.
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